DexCom, Inc. (NASDAQ:DXCM) – Stock analysts at Jefferies Financial Group issued their Q3 2019 earnings per share (EPS) estimates for DexCom in a report released on Tuesday, November 6th. Jefferies Financial Group analyst R. Denhoy expects that the medical device company will earn $0.00 per share for the quarter. Jefferies Financial Group has a “Buy” rating and a $148.00 price objective on the stock. Jefferies Financial Group also issued estimates for DexCom’s Q4 2019 earnings at $0.21 EPS.
DexCom (NASDAQ:DXCM) last announced its earnings results on Tuesday, November 6th. The medical device company reported $0.17 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.29. The business had revenue of $266.70 million during the quarter, compared to analyst estimates of $242.72 million. DexCom had a net margin of 4.72% and a negative return on equity of 2.89%. The firm’s quarterly revenue was up 44.5% on a year-over-year basis.
A number of other brokerages have also weighed in on DXCM. BidaskClub upgraded shares of DexCom from a “hold” rating to a “buy” rating in a research note on Saturday. Northland Securities upgraded shares of DexCom from an “under perform” rating to a “market perform” rating in a research note on Wednesday, September 12th. Stephens boosted their target price on shares of DexCom from $170.00 to $160.00 and gave the company an “overweight” rating in a research note on Wednesday. Piper Jaffray Companies boosted their target price on shares of DexCom to $157.00 and gave the company an “overweight” rating in a research note on Wednesday. Finally, Canaccord Genuity boosted their target price on shares of DexCom from $125.00 to $150.00 and gave the company a “buy” rating in a research note on Thursday, August 23rd. Seven research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the stock. DexCom presently has an average rating of “Buy” and a consensus target price of $132.50.
Shares of DXCM opened at $149.46 on Thursday. The firm has a market cap of $12.85 billion, a price-to-earnings ratio of -257.69 and a beta of 0.60. The company has a quick ratio of 4.62, a current ratio of 4.71 and a debt-to-equity ratio of 0.60. DexCom has a 1-year low of $49.80 and a 1-year high of $152.14.
Several large investors have recently bought and sold shares of the company. Waddell & Reed Financial Inc. boosted its holdings in DexCom by 164.8% in the 2nd quarter. Waddell & Reed Financial Inc. now owns 569,331 shares of the medical device company’s stock worth $54,075,000 after buying an additional 354,331 shares during the period. UBS Group AG boosted its holdings in DexCom by 76.3% in the 1st quarter. UBS Group AG now owns 15,926 shares of the medical device company’s stock worth $1,181,000 after buying an additional 6,890 shares during the period. BlackRock Inc. boosted its holdings in DexCom by 5.9% in the 2nd quarter. BlackRock Inc. now owns 4,116,421 shares of the medical device company’s stock worth $390,978,000 after buying an additional 228,933 shares during the period. Macquarie Group Ltd. boosted its holdings in DexCom by 14.4% in the 2nd quarter. Macquarie Group Ltd. now owns 236,341 shares of the medical device company’s stock worth $22,448,000 after buying an additional 29,825 shares during the period. Finally, Federated Investors Inc. PA boosted its holdings in DexCom by 97.1% in the 2nd quarter. Federated Investors Inc. PA now owns 460,209 shares of the medical device company’s stock worth $43,710,000 after buying an additional 226,740 shares during the period.
In other news, CEO Kevin R. Sayer sold 11,161 shares of the company’s stock in a transaction on Monday, August 13th. The stock was sold at an average price of $123.22, for a total value of $1,375,258.42. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jacob Steven Leach sold 47,600 shares of the company’s stock in a transaction on Friday, September 28th. The stock was sold at an average price of $143.95, for a total value of $6,852,020.00. Following the completion of the sale, the insider now owns 109,284 shares of the company’s stock, valued at $15,731,431.80. The disclosure for this sale can be found here. Insiders sold a total of 157,892 shares of company stock valued at $21,864,030 over the last 90 days. 1.80% of the stock is currently owned by company insiders.
DexCom Company Profile
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Recommended Story: How is an ETF different from a mutual fund?
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.